A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Immunotherapy, particularly the adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), is a very promising therapy for metastatic melanoma. Some patients unable to receive TIL have been successfully treated with autologous peripheral blood lymphocytes (PBL), genetically modified to express human leukocyte antigen (HLA) class I antigen-restricted, melanoma antigen-reactive T-cell receptors; however, substantial numbers of patients remain ineligible due to the lack of expression of the restricting HLA class I allele. We sought to overcome this limitation by designing a non-MHC-restricted, chimeric antigen receptor (CAR) targeting the high molecular weight melanoma-associated antigen (HMW-MAA), which is highly expressed on more than 90% of human melanomas but has a restricted distribution in normal tissues. HMW-MAA-specific CARs containing an antigen recognition domain based on variations of the HMW-MAA-specific monoclonal antibody 225.28S and a T-cell activation domain based on combinations of CD28, 4-1BB, and CD3zeta activation motifs were constructed within a retroviral vector to allow stable gene transfer into cells and their progeny. Following optimization of the HMW-MAA-specific CAR for expression and function in human PBL, these gene-modified T cells secreted cytokines, were cytolytic, and proliferated in response to HMW-MAA-expressing cell lines. Furthermore, the receptor functioned in both CD4(+) and CD8(+) cells, was non-MHC restricted, and reacted against explanted human melanomas. To evaluate this HMW-MAA-specific CAR in patients with metastatic melanoma, we developed a clinical-grade retroviral packaging line. This may represent a novel means to treat the majority of patients with advanced melanoma, most notably those unable to receive current ACT therapies.
Burns
William R
WR
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Zhao
Yangbing
Y
Frankel
Timothy L
TL
Hinrichs
Christian S
CS
Zheng
Zhili
Z
Xu
Hui
H
Feldman
Steven A
SA
Ferrone
Soldano
S
Rosenberg
Steven A
SA
Morgan
Richard A
RA
D000483:Alleles; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology; D045744:Cell Line, Tumor; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D011946:Receptors, Antigen / Q000737:chemistry*; D012190:Retroviridae / Q000235:genetics; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D000099216:Chondroitin Sulfate Proteoglycan 4
D000951:Antigens, Neoplasm; D011946:Receptors, Antigen; D000099216:Chondroitin Sulfate Proteoglycan 4
Nat Med. 2008 Nov;14(11):1264-70
18978797
Int J Cancer. 1981 Sep 15;28(3):293-300
7033148
Blood. 2009 Jul 16;114(3):535-46
19451549
Crit Rev Immunol. 2004;24(4):267-96
15588226
Cancer Res. 2008 Oct 1;68(19):8066-75
18829565
J Invest Dermatol. 1999 May;112(5):744-50
10233766
Mol Ther. 2007 Oct;15(10):1744-50
17637721
Mol Ther. 2007 Apr;15(4):825-33
17299405
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
17062687
Nat Rev Immunol. 2002 Jul;2(7):512-9
12094225
Nat Rev Cancer. 2003 Jan;3(1):35-45
12509765
Int J Cancer. 2003 Jan 20;103(3):399-407
12471624
Nat Rev Cancer. 2008 Apr;8(4):299-308
18354418
J Invest Dermatol. 1985 Oct;85(4):340-6
3900230
Int J Cancer. 1997 Sep 26;73(1):42-9
9334808
J Immunol. 2009 Nov 1;183(9):5563-74
19843940
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
8421711
Science. 2006 Oct 6;314(5796):126-9
16946036
J Clin Oncol. 2006 May 1;24(13):e20-2
16648493
J Clin Oncol. 2008 Nov 10;26(32):5233-9
18809613